Dolph Houben

111 Neoangiogenensis, transplant viability and molecular analysis of bone VCA 5 Conclusion Living bone allotransplantation for the reconstruction of segmental bone loss in a preclinical model can be safely done with short-term immunosuppression due to recipient-derived neo- angiogenesis with relatively low complication rates in a porcine model. The implantation of a patent AV-bundle generates an autogenous neoangiogenic circulation which maintains bone viability and maintenance of important osteoblast and osteoclast activity markers and a significant increase in the expression of endothelial growth factor like 6 ( EGFL-6) after transplantation. However, further experimental research is needed to fully understand the exact behavior of VCA’s with a larger sample size and longer follow-up. Additionally, the systemic and local immune response should be better understood before bone VCA may be safely performed clinically.